News Releases

Investor Alerts

Nov 5, 2020

Avidity Biosciences to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced...
Sep 28, 2020

Avidity Biosciences to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced...
Sep 14, 2020

Avidity Biosciences to Present at Several Upcoming Virtual Scientific Meetings

-Presentations at five upcoming scientific meetings will focus on the broad therapeutic applications of Avidity's AOC platform-

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced...
Sep 8, 2020

Avidity Biosciences Enters into Collaboration to Study the Natural History of Myotonic Dystrophy Type 1

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced...
Sep 3, 2020

Avidity Biosciences to Present at the 2020 Wells Fargo Virtual Healthcare Conference

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced...

Show per page